Nanobiotix 2018 Q4 and Annual Revenues

Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its unaudited revenues for Q4 and the unaudited annual revenues for the year ended December 31, 2018.

2018 Revenues

In €				12/31/2018 (12 months)				12/31/2017 (12 months)
Revenue				105,364				251,967
Of which:
License				-				146
Services				98,734				251,821
Other sales				6,630				-

Revenue for Q4 2018

In €

Q4 2018

Q3 2018

Q2 2018

Q1 2018

Revenues

10,244

21,816

73,304

-

Of which:

License